Ratings Mabwell (Shanghai) Bioscience Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
28.94 ^CNY	-1.53%		-11.15%	-11.47%

05-24	Mabwell Announces 9MW2821 Clinical Data	CI
05-13	Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

	1st Jan change	Capi.	ESG Refinitiv
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.	-11.47%	1.59B	-
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B	B+
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B	B+
ARGENX SE	+18.95%	26.02B	B
BIONTECH SE	-23.86%	19.39B	B+
GENMAB A/S	-19.03%	15.91B	A-
BEIGENE, LTD.	-20.90%	15.09B	B
WUXI APPTEC CO., LTD.	-46.14%	15.06B	A-
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B	C+
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality